(A) Relative liver weight of wild-type and SRC-3−/− mice with or without TCPOBOP treatment. (B) Hepatocyte numbers per visual field in liver sections from wild-type and SRC-3−/− mice were similar with or without TCPOBOP treatment (magnification, ×200). (C) Cumulative BrdU-positive hepatocytes in the livers of SRC-3−/− mice were reduced compared with wild-type mice at 72 h after TCPOBOP treatment (1500 -2000 hepatocyte nuclei per section were counted). Inserted figures showed the immunohistochemial staining of BrdU in liver sections (magnification, ×200). (D) The number of PCNA-positive hepatocyte was lower in SRC-3−/− mice than that in wild-type mice at 36 and 72 h after TCPOBOP treatment. Inserted figures showed the immunohistochemial staining of PCNA at 72 h after TCPOBOP treatment (magnification, ×200). (E) Expression of c-Myc in the livers of SRC-3−/− mice was reduced at 24, 36, and 72 h after TCPOBOP treatment compared with wild-type mice. (F) Expression of Foxm-1 in the livers of SRC-3−/− mice was reduced at 36 and 72 h after TCPOBOP treatment compared with wild-type mice. mRNA expression of c-Myc (E) and Foxm-1 (F) was assessed by real-time PCR. Data are the means + SD of five male mice per group. * p<0.05, ** p<0.01.